Transpire Bio
Myeisha McQueen currently serves as the Head of Early Phase Development at Transpire Bio, a position held since February 2024. Prior to this role, Myeisha McQueen spent nearly a decade at Lupin, where responsibilities included Senior Director, Clinical Development, as well as positions as Director and Associate Director in Clinical Development for Inhalation R&D from October 2014 to February 2024. Earlier experience includes a tenure at Teva Pharmaceuticals from January 2008 to October 2014, where Myeisha McQueen progressed from Manager to Senior Manager. Myeisha McQueen holds a degree from Barry University.
This person is not in any teams
This person is not in any offices
Transpire Bio
We are a team of dedicated professionals with expertise in delivering medicines to the body through the inhaled route. The Leadership Team combined has over 100 years of experience in developing inhaled medicines and bringing these medicines to the U.S. and European markets. Our purpose at Transpire Bio is framed by two core elements: Access and Innovation. For common diseases where adequate therapies exist, we seek to expand access to these complex inhaled medicines globally by developing and commercializing lower-cost generic alternatives. For diseases with few treatment options, we seek to innovate by harnessing existing known mechanisms of action, and dramatically improve the risk-benefit profile of selected molecules by developing these as inhaled therapeutics. Our understanding of the complexities of inhaled drug-device products will allow us to advance these therapies and improve the health of people around the globe.